Key Points {#FPar1}
==========

Dupilumab demonstrated favorable safety and sustained efficacy in adults with moderate-to-severe atopic dermatitis (AD) for up to 3 years.The safety data reported in this open-label study are consistent with previously reported controlled studies of up to 52 weeks.These safety and efficacy data support the long-term, continuous use of dupilumab in adults with moderate-to-severe AD.

Introduction {#Sec1}
============

Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with eczematous lesions and pruritus that impairs quality of life \[[@CR1]\] and often occurs with allergic comorbidities \[[@CR1], [@CR2]\]. Many systemic and topical treatments for AD are not recommended for long-term continuous use due to safety concerns and lack of long-term efficacy data \[[@CR3]\].

Dupilumab is a fully human VelocImmune^®^-derived \[[@CR4], [@CR5]\] monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13. Dupilumab clinical trials have shown that these cytokines are key and central drivers of multiple type 2 inflammatory diseases \[[@CR2], [@CR6], [@CR7]\]. Dupilumab is approved for patients with type 2 inflammatory diseases, including AD, asthma, and chronic rhinosinusitis with nasal polyps \[[@CR8], [@CR9]\]. In multiple randomized, placebo-controlled phase III trials in patients with moderate-to-severe AD, dupilumab with or without topical corticosteroids (TCSs) improved AD skin lesions, symptoms, and quality of life, and had a favorable safety profile \[[@CR10]--[@CR12]\]. Furthermore, in an open-label extension (OLE) study (LIBERTY AD OLE), up to 76 weeks of dupilumab treatment showed continued efficacy in AD signs, symptoms, and quality of life, with favorable safety \[[@CR13]\]. In this study, we report the safety and efficacy of up to 3 years of dupilumab treatment in patients with moderate-to-severe AD from the LIBERTY AD OLE study.

Methods {#Sec2}
=======

Study Design, Patients, and Treatment {#Sec3}
-------------------------------------

LIBERTY AD OLE is an ongoing, multicenter, open-label trial in adults with moderate-to-severe AD (NCT01949311). The protocol is provided in electronic supplementary material 1. The detailed study design and data (cut-off date April 2016) have been previously reported \[[@CR13]\]. We report results with a cut-off date of 1 December 2018 (database lock 13 February 2019), at which time approximately 550 sites in 28 countries in North America, Europe, and Asia--Pacific had participated.

Patients were included if they participated in previous phase I--III dupilumab studies (including patients in the placebo groups) \[[@CR10]--[@CR12], [@CR14]--[@CR21]\] and adequately completed the required parent study assessments or were screened for phase III studies (NCT02277743/NCT02277769) \[[@CR12]\], but not randomized due to randomization closure. Patients were ineligible if they had an adverse event (AE) deemed related to dupilumab that led to treatment discontinuation or had a serious AE deemed related to dupilumab in the parent study.

Patients enrolled from October 2013 received subcutaneous dupilumab 200 mg weekly (400 mg loading dose). Following protocol amendment on 12 December 2013, patients received 300 mg weekly based on the dose regimens selected for phase III studies.

Rescue medications included systemic corticosteroids (SCSs) and nonsteroidal systemic immunosuppressive medications (including phototherapy). Patients who received rescue medication discontinued study treatment for the duration of the rescue treatment plus five half-lives, after which they could resume dupilumab treatment. Protocol Amendment 7 allowed patients who used SCSs as rescue medication to continue treatment with study drug. Other concomitant treatments for AD, including TCSs and topical calcineurin inhibitors (TCIs), were permitted.

The original planned study duration per patient was up to 3 years of treatment or until regulatory approval/commercial availability of dupilumab in the patient's geographic region, whichever came first. Country-specific protocol Amendment 7 for France, Germany, Poland, and Japan permitted those patients who had already completed 3 years of treatment to continue or restart and continue treatment through 31 December 2017. Region-specific Amendment 8 extended the treatment period to 5 years in Poland and Finland, and to September 2018 in France.

Ethics {#Sec4}
------

The study was conducted following ethical principles that derive from the Declaration of Helsinki, the International Conference on Harmonisation guideline, Good Clinical Practice, and local applicable regulatory requirements, including Institutional Review Board approval. All patients provided written informed consent prior to undertaking any study procedures.

Outcomes Assessed in This Analysis {#Sec5}
----------------------------------

The primary outcome was incidence and rate (events per patient-year \[PY\]) of treatment-emergent AEs (TEAEs). Key secondary outcomes included incidence and rate of serious TEAEs, percentage of patients with an Investigator's Global Assessment (IGA) score of 0/1, and percentage of patients with ≥ 75% improvement in the Eczema Area and Severity Index (EASI) from baseline (EASI-75). Other secondary outcomes were change and percentage change from baseline in EASI, percentage of patients with ≥ 50% or ≥ 90% improvement in EASI from baseline (EASI-50 and EASI-90, respectively), change and percentage change from baseline in the weekly average Pruritus Numerical Rating Scale (NRS), percentage of patients with ≥ 3-point improvement (reduction) in weekly average Pruritus NRS from baseline or with a value of 0, change from baseline in Patient-Oriented Eczema Measure (POEM) and Dermatology Life Quality Index (DLQI), and percentage of patients requiring rescue treatment. Post hoc outcomes included the percentage of patients with ≥ 2-point improvement from baseline IGA score and percentage of patients with a weekly average Pruritus NRS score ≤ 3 (mild itch) \[[@CR22]\]. IGA and EASI assessments at the end of the treatment visit (week 148) were removed and subsequently restored from protocol Amendments 6 and 7, respectively.

Statistical Analysis {#Sec6}
--------------------

All analyses were performed in the safety analysis set (patients who received one or more doses of study drug). Duration-adjusted analyses for safety parameters were computed over the duration of study participation. Efficacy analyses are descriptive and were performed using all observed data at each time point, without any imputation for missing values; efficacy parameters were assessed up to week 148. Sensitivity analyses on patients enrolled prior to December 2015 (to include only those enrolled 3 years prior to the data cut-off date of December 2018) were performed on selected key efficacy endpoints (mean and change from baseline of the parent study in EASI and weekly average Pruritus NRS) using multiple imputation and last observation carried forward methods. Because the OLE trial lacked a control arm, LIBERTY AD CHRONOS trial (NCT02260986) \[[@CR10]\] safety results from the final analysis are provided as a comparison. CHRONOS was selected because it was the largest and longest (52 weeks) controlled study that required the use of concomitant TCS. All analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

Patients {#Sec8}
--------

A total of 2826 patients were screened from 14 parent studies, of whom 2678 (94.8%) were included in the OLE (Fig. [1](#Fig1){ref-type="fig"}). One screened patient was enrolled but not treated, leaving 2677 patients in the analysis set.Fig. 1Study flow diagram

At database lock, 82.4% of patients (2207/2677) had completed up to week 52; 1028 (38.4%) up to week 100; and 347 (13.0%) up to week 148 (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). A total of 1061 (39.6%) patients completed the study (treatment and safety follow-up); 291 (10.9%) patients were receiving ongoing treatment; and 1325 (49.5%) patients had withdrawn from the study (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). Most patients (807, 30.1%) withdrew from the study due to study termination by the sponsor upon regulatory approval/commercial availability of the study drug. 'Withdrawal by subject' accounted for 221 (8.3%) withdrawals (see footnote, Table [1](#Tab1){ref-type="table"}). Discontinuation due to AEs (109, 4.1%) and lack of efficacy (57, 2.1%) were infrequent. The mean self-reported study drug compliance was 98.2%, with most patients (≥ 80%) self-reporting injection compliance during the treatment period.Table 1Study completion, reasons for withdrawal, and baseline demographics and disease characteristicsDupilumab 300 mg qw \[*N *= 2677\]^a^**OLE study completion status**Completed up to 1 year2207 (82.4)Completed up to 2 years1028 (38.4)Completed up to 3 years347 (13.0)Completed study^b^1061 (39.6)Patients ongoing291 (10.9)Withdrawn from study1325 (49.5) Study terminated by sponsor (regulatory approval/commercialization)807 (30.1) Withdrawal by subject^c^221 (8.3) Adverse event^d^109 (4.1) Lost to follow-up64 (2.4) Lack of efficacy57 (2.1) Protocol deviation32 (1.2) Pregnancy17 (0.6) Physician decision14 (0.5) Unknown4 (0.1)**Demographics at parent study baseline**Age, years \[mean (SD)\]39.2 (13.4)Male1611 (60.2)Race White1936 (72.3) Black or African American147 (5.5) Asian541 (20.2) Other33 (1.2) Not reported20 (0.7)Height, cm \[mean (SD)\]170.7 (9.88)Weight, kg \[mean (SD)\]77.1 (18.4)BMI, kg/m^2^ \[mean (SD)\]26.4 (5.59)Treatment in the parent study Previously treated with dupilumab1679 (62.7)  Dupilumab 300 mg qw807 (30.1)  Dupilumab 300 mg q2w536 (20.0)  Other dupilumab doses^e^336 (12.6) Received placebo qw in the parent study968 (36.2) Screen failure^f^30 (1.1)Patients with concurrent atopic/allergic disease history at parent study baseline2627 (98.1) Allergies (other)1749 (65.3) Allergic rhinitis1332 (49.8) Asthma1105 (41.3) Food allergy1010 (37.7) Allergic conjunctivitis740 (27.6) Hives368 (13.7) Chronic rhinosinusitis173 (6.5) Atopic keratoconjunctivitis78 (2.9) Nasal polyps63 (2.4) Eosinophilic esophagitis13 (0.5)Concomitant topical treatments for AD during the study Patients who used TCSs1416 (52.9) Patients who used TCIs431 (16.1) Patients who used TCSs or TCIs1487 (55.5) Patients who used TCSs and TCIs360 (13.4)**Disease characteristicsCurrent study (OLE)Parent study**Duration of AD, years \[mean (SD)\]29.9 (14.8)29.0 (14.8)EASI (0--72) \[mean (SD)\]16.4 (14.6)32.8 (13.2)Patients with IGA score 0--4 \[mean (SD)\]2.7 (0.95)3.49 (0.50) 0 or 1320 (12.0)0 2610 (22.8)0 31288 (48.1)1343 (50.2) 4459 (17.1)1301 (48.6) Missing030 (1.1)Patients with weekly average Pruritus NRS score (0--10) \[mean (SD)\]5.0 (2.45)7.1 (1.93) ≥ 31769 (66.1)2528 (94.4) ≥ 41505 (56.2)2437 (91.0)POEM total score (0--28) \[mean (SD)\]14.7 (8.00)20.5 (5.89)DLQI (0--30) \[mean (SD)\]8.5 (7.11)14.7 (7.38)Data are expressed as *n* (%) unless otherwise specified*AD* atopic dermatitis, *BMI* body mass index, *DLQI* Dermatology Life Quality Index, *EASI* Eczema Area and Severity Index, *IGA* Investigator's Global Assessment, *NRS* Numerical Rating Scale, *OLE* open-label extension, *POEM* Patient-Oriented Eczema Measure, *q2w* every 2 weeks, *q4w* every 4 weeks, *q8w* every 8 weeks, *qw* weekly, *SD* standard deviation, *TCI* topical calcineurin inhibitor, *TCS* topical corticosteroid^a^Includes patients from NCT01259323 \[[@CR14], [@CR19]\] (*N* = 7); NCT01859988 \[[@CR20]\] (*N* = 296); NCT01385657 \[[@CR14], [@CR19]\] (*N* = 12); NCT01548404 \[[@CR14]\] (*N* = 51); NCT01639040 \[[@CR14]\] (*N* = 17); NCT02260986 \[[@CR10]\] (*N* = 581); NCT01979016 \[[@CR18]\] (*N* = 44); NCT02210780 \[[@CR15]\] (*N* = 168); NCT02277743 \[[@CR12]\] (*N* = 353); NCT02407756 \[[@CR16]\] (*N* = 5); NCT02395133 \[[@CR22]\] (*N* = 415); NCT02277769 \[[@CR12]\] (*N* = 402); NCT02755649 \[[@CR11]\] (*N* = 313); NCT02647086 \[[@CR17]\] (*N* = 13)^b^These patients completed the treatment and end-of-study periods^c^Includes reasons of relocation, desire for pregnancy, did not want to discontinue treatment for 12 weeks, work/school conflict, and personal reasons not specified^d^Includes patients withdrawn from the study, both those receiving treatment at the time of withdrawal and those not receiving treatment during the safety follow-up period^e^Includes the following dupilumab doses in the parent study: 75 mg qw, 100 mg q4w, 150 mg qw, 200 mg q2w, 200 mg qw, 300 mg q8w, 300 mg q4w, 2 mg/kg, 4 mg/kg^f^These patients had screen failed in the parent study because the enrollment target was met, but they were permitted to enter the OLE

The majority of patients were male (60.2%) and white (72.3%); of the 147 enrolled patients who self-reported as black/African American, 134 (91.2%) enrolled in the US, 9 (6.1%) in Canada, 3 (2.0%) in the UK, and 1 (0.7%) in Austria; 541 patients self-reported as Asian, the majority from Japan (45.5%), South Korea (17.7%), US (15.5%), and Canada (14.6%) \[Table [1](#Tab1){ref-type="table"}\]. A total of 62.7% of patients received dupilumab in the parent study, and 36.2% received placebo (Table [1](#Tab1){ref-type="table"}). At baseline, almost all patients had one or more atopic/allergic comorbidities (Table [1](#Tab1){ref-type="table"}). During the study, 52.9% and 16.1% of patients used TCSs and TCIs, respectively, with 55.5% of patients using TCSs or TCIs (Table [1](#Tab1){ref-type="table"}).

Safety Assessment {#Sec9}
-----------------

Overall, 13,826 TEAEs were reported in 2264 patients (84.6%), with an exposure-adjusted rate of 173.7 number of patients (nP)/100 PY (Table [2](#Tab2){ref-type="table"}). Most TEAEs were of mild-to-moderate severity; severe TEAEs were reported in 9.2% of patients. TEAEs led to treatment discontinuation in 95 patients (3.5%). Two deaths were reported, both unrelated to study treatment (see footnote, Table [2](#Tab2){ref-type="table"}).Table 2Safety assessmentCurrent study (OLE)CHRONOS (52 weeks)300 mg qw \[*N* = 2677\]Placebo + TCS \[*n* = 315\]300 mg qw + TCS \[*n* = 315\]EventsPts with ≥ 1 event, \[*n* (%)\]nE/100 PYnP/100 PYEventsPts with ≥ 1 event \[*n* (%)\]nE/100 PYnP/100 PYEventsPts with ≥ 1 event, \[*n* (%)\]nE/100 PYnP/100 PYTEAEs13,8262264 (84.6)270.1173.71520268 (85.1)531.9325.11,500263 (83.5)504.5322.43Serious TEAEs354256 (9.6)6.925.282416 (5.1)8.405.751110 (3.2)3.703.40Severe TEAEs355246 (9.2)6.945.084628 (8.9)16.1010.312417 (5.4)8.075.88TEAEs leading to study drug discontinuation11695 (3.5)2.271.872925 (7.9)10.159.14109 (2.9)3.363.06Serious TEAEs related to treatment3631 (1.2)0.700.6133 (1.0)1.051.0622 (0.6)0.670.68Death^a^22 (\< 0.1)0.040.04000011 (0.3)0.340.34Most common TEAEs by PT (≥ 5% of patients in the OLE) Nasopharyngitis1543752 (28.1)30.1419.169062 (19.7)31.4924.938662 (19.7)28.9224.16 Atopic dermatitis736438 (16.4)14.389.61243147 (46.7)85.0374.329155 (17.5)30.6020.71 Upper respiratory tract infection532350 (13.1)10.397.564832 (10.2)16.8012.036543 (13.7)21.8615.85 Headache408216 (8.1)7.974.543119 (6.0)10.856.984825 (7.9)16.148.97Conjunctivitis^b^826521 (19.5)16.1411.962925 (7.9)10.159.249161 (19.4)30.6023.37Injection-site reactions (HLT)855260 (9.7)16.705.5810525 (7.9)36.749.3923263 (20.0)78.0225.46Herpes viral infections (HLT)715333 (12.4)13.977.213225 (7.9)11.209.174322 (7.0)14.467.72Skin infections291231 (8.6)5.694.81NA57 (18.1)NA20.21NA26 (8.3)NA7.87Eczema herpeticum (PT)1412 (0.4)0.270.2466 (1.9)2.102.130000Most common serious TEAEs by PT (≥ 0.2% of patients in the OLE) Squamous cell carcinoma of skin148 (0.3)0.270.16000011 (0.3)0.340.34 Osteoarthritis109 (0.3)0.200.18000011 (0.3)0.340.34 Dermatitis atopic76 (0.2)0.140.1211 (0.3)0.350.3521 (0.3)0.670.34 Syncope65 (0.2)0.120.1000000000 Inguinal hernia55 (0.2)0.100.1000000000 Appendicitis55 (0.2)0.100.1000000000*HLT* MedDRA High Level Term, *MedDRA* Medical Dictionary for Regulatory Activities, *NA* not available, *nE* number of events, *nP* number of patients, *OLE* open-label extension, *PT* MedDRA Preferred Term, *pts* patients, *PY* patient-year, *qw* weekly, *TCS* topical corticosteroid, *TEAE* treatment-emergent adverse event^a^One death in the OLE due to natural causes in an 88-year-old female and one due to unknown causes in a 60-year-old female approximately 5 months after the final dose of study drug; death in CHRONOS previously reported \[[@CR10]\]^b^Includes PT: conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis viral, and atopic keratoconjunctivitis

The most common TEAEs were nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions (Table [2](#Tab2){ref-type="table"}), all previously reported in dupilumab trials. The exposure-adjusted incidence rates of these AEs were lower in the OLE compared with the 1-year CHRONOS trial (Table [2](#Tab2){ref-type="table"}).

The exposure-adjusted incidence rate of conjunctivitis (reported as a cluster of Medical Dictionary for Regulatory Activities preferred terms, including conjunctivitis, conjunctivitis allergic, conjunctivitis bacterial, conjunctivitis viral, and atopic keratoconjunctivitis) was 11.96 nP/100 PY, comparable with that observed in the CHRONOS study placebo arm (9.24 nP/100 PY) and approximately 50% lower than that observed in the 300 mg weekly treatment arm of CHRONOS (23.37 nP/100 PY). Most conjunctivitis events were mild-to-moderate in severity and did not result in treatment discontinuation. In \> 85% of cases, conjunctivitis resolved with standard ophthalmic treatments while the patient remained on study drug. The most commonly used ophthalmic treatments included intraocular corticosteroids, anti-allergy medications, and anti-infectives. Severe conjunctivitis occurred in 26 (1.0%) patients. Fourteen (0.5%) patients permanently discontinued the study drug due to conjunctivitis. The time to onset of all conjunctivitis events ranged from 9 to 574 days after the initiation of treatment in the OLE.

Rates of serious TEAEs and serious TEAEs considered by the investigator as related to treatment were similar between patients in the OLE and those receiving dupilumab in CHRONOS (Table [2](#Tab2){ref-type="table"}). Overall, 354 serious TEAEs were reported in 256 patients (9.6%). Thirty-six serious TEAEs considered related to study drug by the investigator occurred in 31 (1.2%) patients, with an exposure-adjusted incidence rate of serious TEAEs in OLE (0.61 nP/100 PY) lower than that observed in the placebo arm of CHRONOS (1.06 nP/100 PY) and comparable with the dupilumab group (0.68 nP/100 PY). Most serious treatment-related TEAEs occurred in individual patients. The most common serious TEAEs included osteoarthritis (0.18 nP/100 PY), squamous cell carcinoma of the skin (0.16 nP/100 PY), exacerbation of AD (0.12 nP/100 PY), syncope (0.10 nP/100 PY), inguinal hernia (0.10 nP/100 PY), and appendicitis (0.10 nP/100 PY). Seven of nine patients with a serious TEAE of osteoarthritis had a medical history of this condition.

Efficacy {#Sec10}
--------

AD skin lesion severity and AD-related symptoms improved over the course of the OLE, characterized by rapid initial improvement followed by progressive incremental improvement thereafter. By week 100, 58.1% of patients achieved IGA scores of 0 or 1, increasing to 74.1% by week 148 (Table [3](#Tab3){ref-type="table"}). By week 100, 77.2% of patients achieved a ≥ 2-point improvement in IGA from baseline of the parent study, increasing to 87.9% at week 148 (Table [3](#Tab3){ref-type="table"}).Table 3Efficacy assessmentDupilumab 300 mg qw \[*N* = 2677\]Week 100 \[*n* = 1028\]Week 124 \[*n* = 529\]Week 148^a^ \[*n* = 347\]Patients achieving IGA 0 or 1 \[*n/N1* (%)\]589/1014 (58.1)271/458 (59.2)43/58 (74.1)Patients achieving a reduction in IGA of ≥ 2 from baseline of the parent study \[*n/N1* (%)\]769/996 (77.2)359/457 (78.6)58/66 (87.9)Patients achieving EASI-50 \[*n/N1* (%)\]979/994 (98.5)445/453 (98.2)57/58 (98.3)Patients achieving EASI-75 \[*n/N1* (%)\]908/994 (91.3)416/453 (91.8)56/58 (96.6)Patients achieving EASI-90 \[*n/N1* (%)\]724/994 (72.8)337/453 (74.4)51/58 (87.9)EASI (primary analysis), observed values \[mean (SD)\]2.6 (3.6)2.3 (3.5)1.4 (3.2) OC (sensitivity analysis) \[mean (SE)\]2.6 (0.1)2.3 (0.2)1.5 (0.4) LOCF (sensitivity analysis) \[mean (SE)\]3.6 (0.2)3.6 (0.2)3.6 (0.2) MI (sensitivity analysis) \[mean (SE)\]2.9 (0.1)2.8 (0.1)3.5 (0.1)Change in EASI from baseline of the parent study, observed values \[mean (SD)\]− 31.3 (14.1)− 30.0 (13.6)− 29.2 (14.2) LOCF (sensitivity analysis) \[mean (SE)\]− 29.8 (0.4)− 29.8 (0.4)− 29.8 (0.4) MI (sensitivity analysis) \[mean (SE)\]− 30.6 (0.4)− 30.7 (0.4)− 30.1 (0.4)Percentage change in EASI from baseline of the parent study,  % \[mean (SD)\]− 91.5 (12.6)− 92.3 (11.0)− 95.4 (9.3)Weekly Pruritus NRS (primary analysis), observed values \[mean (SD)\]2.3 (1.9)2.3 (1.8)2.2 (1.8) OC (sensitivity analysis), mean (SE)2.3 (0.1)2.3 (0.1)2.1 (0.1) LOCF (sensitivity analysis), mean (SE)2.5 (0.1)2.6 (0.1)2.6 (0.1) MI (sensitivity analysis), mean (SE)2.4 (0.1)2.6 (0.1)2.5 (0.1)Change in weekly Pruritus NRS from baseline of the parent study (primary analysis), observed values \[mean (SD)\]− 4.7 (2.3)− 4.5 (2.4)− 4.4 (2.4) LOCF (sensitivity analysis) \[mean (SE)\]− 4.7 (0.1)− 4.6 (0.1)− 4.6 (0.1) MI (sensitivity analysis) \[mean (SE)\]− 4.8 (0.1)− 4.6 (0.1)− 4.7 (0.1)Percent change in weekly Pruritus NRS from baseline of the parent study, % \[mean (SD)\]− 65.7 (30.2)− 64.2 (33.4)− 65.4 (28.5)Patients achieving ≥ 3 reduction in weekly Pruritus NRS from baseline of the parent study \[*n/N1* (%)\]604/764 (79.1)313/416 (75.2)168/224 (75.0)Patients achieving weekly average Pruritus NRS ≤ 3 \[*n/N1* (%)\]686/888 (77.3)395/510 (77.5)217/265 (81.9)POEM score \[mean (SD)\]5.4 (5.1)5.1 (5.3)N/ADLQI \[mean (SD)\]2.9 (3.9)2.9 (4.3)N/A*DLQI* Dermatology Life Quality Index, *EASI* Eczema Area and Severity Index, *EASI*-*50* ≥ 50% reduction in EASI from baseline, *EASI*-*75* ≥ 75% reduction in EASI from baseline, *EASI*-*90* ≥ 90% reduction in EASI from baseline, *IGA* Investigator's Global Assessment, *LOCF* last observation carried forward, *MI* multiple imputation, *N1* number of patients with non-missing values, *NRS* Numerical Rating Scale, *POEM* Patient-Oriented Eczema Measure, *OC* observed cohort, *qw* weekly, *SD* standard deviation, *SE* standard error^a^The relatively low patient numbers at week 148 for IGA and EASI resulted from the temporary removal of these assessments from the end-of-treatment visit with the adoption of Amendment 6 that were restored as of Amendment 7

Mean EASI at baseline of the parent study was 33.4, decreasing to 5.8 by week 16 of the OLE study and 1.5 by week 148 (observed cohort, Fig. [2](#Fig2){ref-type="fig"}). Mean weekly average Pruritus NRS at baseline of the parent study was 7.2, decreasing to 3.0 by week 10 and 2.1 by week 148 (observed cohort, Fig. [3](#Fig3){ref-type="fig"}). A sensitivity analysis on patients enrolled 3 years prior to the data cut-off date to assess any bias on treatment outcomes due to patient withdrawal showed EASI and weekly average Pruritus NRS results consistent with the observed data (Table [3](#Tab3){ref-type="table"}; Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). Improvements in other EASI and Pruritus NRS assessments were sustained over the treatment period (Table [3](#Tab3){ref-type="table"}). By week 148, 98.3%, 96.6%, and 87.9% of patients had achieved EASI-50/75/90, respectively, and 81.9% of patients had a weekly average Pruritus NRS ≤ 3, with an absolute mean score of 2.2 (mild itch). By week 124, mean POEM had decreased from 20.5 at baseline of the parent study to 5.1, and mean DLQI from 14.7 to 2.9 (Table [3](#Tab3){ref-type="table"}).Fig. 2Mean EASI over time. \*The relatively low patient number at week 148 resulted from the temporary removal of this assessment from the end-of-treatment visit with the adoption of Amendment 6 that was restored as of Amendment 7. *BL* baseline, *EASI* Eczema Area and Severity Index, *LOCF* last observation carried forward, *MI* multiple imputation, *OC* observed cohort, *PSBL* parent study baseline, *SE* standard errorFig. 3Mean weekly average Pruritus NRS over time. *BL* baseline, *LOCF* last observation carried forward, *MI* multiple imputation, *NRS* Numerical Rating Scale, *OC* observed cohort, *PSBL* parent study baseline, *SE* standard error

A total of 200 (7.5%) patients received rescue medication, which was administered at the discretion of the investigator, and included SCSs (187, 7.0%) and/or non-steroidal immunosuppressants (21, 0.8%).

Discussion {#Sec11}
==========

In this analysis, dupilumab 300 mg weekly (more frequent than the approved regimen of every other week) demonstrated a favorable safety profile and sustained efficacy in moderate-to-severe AD for up to 3 years. Safety data reported in this open-label study are consistent with controlled studies of up to 52 weeks \[[@CR10]--[@CR12], [@CR22]\]. Data were consistent with the known dupilumab safety profile; nasopharyngitis, AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reactions were the only AEs in ≥ 5% of patients.

The exposure-adjusted rates of TEAEs and serious TEAEs in this study were consistent with previously reported rates for dupilumab weekly plus TCS (504.5 number of events \[nE\]/100 PY and 3.7 nE/100 PY, respectively) and lower than placebo plus TCS (531.9 nE/100 PY and 8.4 nE/100 PY, respectively) at 52 weeks. Compliance with study treatment was high (98%) and the rate of treatment discontinuation due to AEs was low (3.5%). Furthermore, few patients (7.5%) receiving dupilumab in this trial required use of systemic rescue medication, demonstrating that dupilumab alone or with concomitant TCSs provides long-term disease control in patients with moderate-to-severe AD.

Most conjunctivitis events reported in this study were mild-to-moderate in severity and did not result in treatment discontinuation. The occurrence of conjunctivitis in dupilumab clinical trials has been reported elsewhere \[[@CR23]\]. In this analysis, the exposure-adjusted incidence of conjunctivitis (16.14 nE/100 PY) was lower than in a previous 52-week controlled trial (30.60 nE/100 PY) and in the 76-week analysis of this trial (20.8 nE/100 PY) \[[@CR13]\], indicating that event frequency may diminish with continued dupilumab treatment. Similarly, the exposure-adjusted incidence of injection-site reactions (16.70 nE/100 PY) decreased compared with the 52-week controlled trial (78.02 nE/100 PY) and the 76-week analysis of the OLE (36.5 nE/100 PY), suggesting decreased event frequency over time.

The most common serious TEAEs included squamous cell carcinoma of the skin. Of note, an increased incidence of non-melanoma skin cancers in patients with AD has been reported in the literature \[[@CR24]--[@CR26]\].

Dupilumab showed substantial and sustained improvement in AD signs and symptoms from the baseline of the parent study, with continued incremental improvement beyond 52 weeks of treatment. Sensitivity analyses of EASI and weekly average Pruritus NRS were consistent with analyses of observed values, demonstrating that patient withdrawal, the majority unrelated to treatment, did not influence the results.

In this study, patients received dupilumab 300 mg weekly, different from the currently approved 300 mg every 2 weeks regimen in adults. Controlled studies have demonstrated no differences in safety or efficacy between these regimens \[[@CR10]--[@CR12]\], suggesting that dupilumab 300 mg every 2 weeks would achieve results similar to those reported here. Of note, the 300-mg weekly dose was originally chosen for this study to increase the likelihood of identifying safety signals and to generate safety data that could adequately support both dose regimens.

The strengths of this study include its size and duration, whereas limitations include the open-label design and lack of a control arm. Furthermore, fewer patients were available at later time points due to timing of this interim analysis, the requirement for patient withdrawal upon regulatory approval of dupilumab in the enrollment country, and the temporary removal of IGA and EASI assessments at week 148.

Conclusions {#Sec12}
===========

The favorable safety and sustained efficacy of dupilumab observed up to 3 years in adults with moderate-to-severe AD support the long-term continuous use of dupilumab in this chronic, debilitating disease.
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